- Home
- TCI vs CERS Comparison
TCI vs CERS Comparison
Compare TCI & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCI | CERS |
|---|---|---|
| Founded | 1983 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.7M | 276.0M |
| IPO Year | 1994 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TCI | CERS |
|---|---|---|
| Price | $34.70 | $2.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.2K | ★ 2.9M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.29 | 27.27 |
| EPS | ★ 0.02 | N/A |
| Revenue | $49,060,000.00 | ★ $51,326,000.00 |
| Revenue This Year | N/A | $19.95 |
| Revenue Next Year | N/A | $8.84 |
| P/E Ratio | $1,761.50 | ★ N/A |
| Revenue Growth | 4.23 | ★ 30.68 |
| 52 Week Low | $31.48 | $1.15 |
| 52 Week High | $59.65 | $3.15 |
Technical Indicators
Market Signals| Indicator | TCI | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 56.34 |
| Support Level | $35.00 | $1.89 |
| Resistance Level | $38.38 | $2.68 |
| Average True Range (ATR) | 0.76 | 0.21 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 26.40 | 43.70 |
Price Performance
Historical ComparisonAbout TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.